Zeus Hygia’s BioSolve Technology improves bioavailability for active ingredients
10 May 2021 --- Zeus Hygia Lifesciences has unveiled its patent-pending BioSolve Technology, which offers higher bioavailability for active ingredients by using food-grade encapsulating excipients.
The launch is a response to the increasing number of science-backed ingredient launches coupled with the rising consumer demand for non-pill supplements.
“Our novel platform for improving the solubility and bioavailability of poorly soluble actives offers not only a new technology, but one of the most advanced and scalable platform technologies to increase bio-efficacy, potency and bioavailability,” says Arunkanth Krishnakumar, Zeus Hygia’s co-founder and director of business development and strategies.
The platform technology allows the ingredients to be used effectively in a wide range of consumer-friendly product delivery forms, including tablets and capsules.
Consumers may get minimal therapeutic benefits from products with poor solubility.
Harnessing novel phase coacervation techniques
BioSolve Technology works by encapsulating water-insoluble actives in a food-grade water-soluble matrix using novel phase coacervation techniques.
This technology helps to deliver actives in situ at a submicron range with increased water solubility and maximum efficacy.
It hinges on a carrier with emulsifying properties that forms an adequate hydrophilic/lipophilic balance around the bioactive molecules, leading to enhanced absorption by the gut wall.
The improved bioavailability is due to several factors, including an increase in water solubility with better dissolution properties, as well as finer and uniform particles with larger surface area.
The carrier is also generally recognized as safe (GRAS) and widely used in food applications across the globe.
Another benefit of BioSolve Technology is that manufacturers can use less of an ingredient for the same deliverable impact. This means that users can consume less than the normal dose with uncompromised bioavailability.
Consumers look for bioavailability
“The fact that more ingredients are being introduced into the marketplace for novel product development is attractive, yet a fair number of those exhibit poor solubility and bioavailability,” explains Krishnakumar.
He argues that as end-users, consumers get minimal therapeutic benefits.
However, Shankaranarayanan Jeyakodi, Zeus Hygia’s co-founder and director of technical operations, observes that consumers are “sophisticated” in their knowledge of how supplements work as well as why to take them.
“They are equally passionate about obtaining benefits of supplementation in a variety of forms. Zeus BioSolve Technology offers manufacturers an opportunity to develop health-promoting products. In other words, we have removed the formulation limitations.”
Bioavailability has long been a hot topic in the nutrition industry. Last month, a clinical trial found Naturex’s TurmiPure Gold to be 24 times more bioavailable than a standard turmeric extract over 24 hours.
Meanwhile, Santé Laboratories’ liposomal delivery system was recently shown to provide up to 80 percent absorption of cannabinoids while overcoming the hydrophobic properties of these compounds.
Edited by Katherine Durrell
